| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02473783 | Major Depressive Disorder | Drug: Sertraline HCl|Other: I-123-ADAM SPECT | Tri-Service General Hospital|Institute of Nuclear Energy Research, Taiwan | Phase 2 | 2011-10-01 | 2015-06-16 |
| NCT01275248 | Obsessive-compulsive Disorder | Drug: Ondansetron|Drug: Placebo | Transcept Pharmaceuticals | Phase 2 | 2011-01-01 | 2013-01-16 |
| NCT01296802 | Amphetamine-Related Disorders|Amphetamine Abuse | Drug: dexfenfluramine | University of Zurich | | 2006-04-01 | 2011-12-14 |
| NCT02015546 | Major Depressive Disorder (MDD) | Drug: Vilazodone | Duke University | Phase 3 | 2012-12-01 | 2015-03-25 |
| NCT03041870 | Healthy Volunteers | Device: PET-fMRI scan | Hospices Civils de Lyon | | 2017-02-01 | 2017-02-02 |
| NCT00735670 | Spinal Cord Injury | Drug: Venlafaxine HCl|Other: Placebo | University of Michigan|U.S. Department of Education | | 2008-06-01 | 2016-10-07 |
| NCT02393612 | Peripheral Arterial Disease | Drug: DP-R202|Drug: Anplag tab | Alvogen Korea | Phase 3 | 2012-10-01 | 2016-10-31 |
| NCT01425827 | Pain Reduction|Function Improvement | Drug: duloxetine HCL|Drug: placebo | Faculty of Medicine, University of Alexandria | | 2010-11-01 | 2011-08-27 |
| NCT02186366 | Anxiety Disorders | Other: Abdominal Massage Therapy|Drug: Buspirone | Sun Qing|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | 2014-09-01 | 2014-09-01 |
| NCT02359513 | Bulimia Nervosa | Drug: Antidepressants|Drug: Positron Emission Tomography (PET) | Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France | Phase 4 | 2015-11-01 | 2016-09-13 |
| NCT00167856 | Neuropathic Pain|Pain|Spinal Cord Injuries | Drug: Venalafaxine hydrochloride | VA Office of Research and Development | | 2005-06-01 | 2014-03-26 |
| NCT00967499 | Postoperative Nausea and Vomiting | Drug: ondansetron|Drug: palonosetron | Eisai Inc. | Phase 2 | 2009-07-01 | 2010-05-06 |
| NCT00549718 | Schizophrenia | Drug: Lurasidone HCl | Sunovion | Phase 3 | 2007-10-01 | 2014-06-05 |
| NCT01074073 | Schizophrenia | Drug: Lurasidone HCl | Sunovion | Phase 1 | 2008-08-01 | 2011-09-06 |
| NCT02655991 | Stress Disorders, Post-Traumatic | Behavioral: Telephone Case Monitoring|Behavioral: Treatment as Usual | VA Palo Alto Health Care System|Durham VA Medical Center|VA Puget Sound Health Care System | 2008-03-01 | 2016-01-12 |
| NCT00711269 | Schizophrenia | Drug: SM-13496 (lurasidone HCl)|Drug: SM-13496 (lurasidone HCl)|Drug: Placebo|Drug: Risperidone | Sumitomo Dainippon Pharma Co., Ltd. | Phase 3 | 2008-07-01 | 2012-06-11 |
| NCT01082263 | Schizophrenia Patients | Drug: Lurasidone HCl | Sunovion | Phase 1 | 2008-10-01 | 2011-09-06 |
| NCT00653419 | To Determine Bioequivalence Under Fasting Conditions | Drug: buspirone HCl|Drug: Buspar | Par Pharmaceutical, Inc.|Phoenix International Life Sciences, Inc. | Phase 1 | 1998-06-01 | 2008-04-01 |
| NCT00615433 | Schizophrenia | Drug: Lurasidone|Drug: Olanzapine|Drug: Placebo comparator|Drug: Lurasidone 40 mg tablets | Sunovion | Phase 3 | 2008-01-01 | 2015-05-19 |
| NCT00652730 | To Determine Bioequivalence Under Fed Conditions. | Drug: Buspirone HCl|Drug: Buspirone HCl|Drug: Buspar | Par Pharmaceutical, Inc.|Phoenix International Life Sciences, Inc. | Phase 1 | 1998-07-01 | 2008-04-01 |
